Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Mechanism Discovered for Cancer Cell Metastasis

By BiotechDaily International staff writers
Posted on 18 Jul 2012
Print article
Image: Electron microscopy of a tumor cell (blue, green) on the way to extravasate through an alveolar endothelium blood capillary (purple, red). Tumor cell protrusions are seen forming their way through the endothelial cell (Photo courtesy of the University of Zurich.)
Image: Electron microscopy of a tumor cell (blue, green) on the way to extravasate through an alveolar endothelium blood capillary (purple, red). Tumor cell protrusions are seen forming their way through the endothelial cell (Photo courtesy of the University of Zurich.)
Image: Tumor cells (green) adhere on the endothelium (red) that becomes activated and permeable via CCL2-CCR2 signaling. Tumor cell extravasation is facilitated by recruited monocytic cells (blue). Technique: Adaptation of confocal image stacks creating an artificial surface. (Photo courtesy of the University of Zurich.)
Image: Tumor cells (green) adhere on the endothelium (red) that becomes activated and permeable via CCL2-CCR2 signaling. Tumor cell extravasation is facilitated by recruited monocytic cells (blue). Technique: Adaptation of confocal image stacks creating an artificial surface. (Photo courtesy of the University of Zurich.)
Scientists have for the first time discovered a mechanism by which cancer cells metastasize to other parts of the body, where they form the secondary tumors responsible for the vast majority of cancer-related deaths.

Until now, molecular level processes leading to the metastatic spread into certain organs have been unknown, it being unclear as to how the secondary cells are able to leave the bloodstream and enter the tissue of other organs. A European team of physiologists and neuropathologists, primarily through the University of Zurich (Switzerland), have now identified a biochemical pathway underlying the origin of metastasis formation whereby at least some, if not all, types of cancer cells metastasize out of the bloodstream. The team, led by principal investigators Dr. Lubor Borsig and Dr. Mathias Heikenwalder, demonstrated that intestinal cancer cells manipulate specific “doorman receptors” on the endothelium of the blood vessels.

Elevated levels of the chemokine CCL2 are known to be characteristic of metastasizing breast, prostate, and intestinal bowel types of cancer cells; clinically, high CCL2 values have been primarily taken as an indication of strong tumor growth and a poor prognosis. Increased CCL2 expression has also been correlated with recruitment of CCR2+Ly6Chi monocytes, CCR2 being a CCL2-activated receptor. Based on in vivo and in vitro experiments, the current study has now shown CCL2 to be far more than an indicator of the cancer’s aggressiveness – CCL2 was found to be part of a signal transduction mechanism critical in helping at least some types of cancer cells metastasize.

The study describes CCL2 upregulation in metastatic UICC stage IV colon carcinomas and demonstrates that tumor cell-derived CCL2 activates the CCR2+ endothelium and thereby leads to increased vascular permeability in vivo. CCR2 acts as a “doorman receptor” activated by CCL2. The role of the CCR2 doorman in a healthy organism is not known and has only now been detected on the endothelium for the first time. Dr. Borsig suspects that the doorman is involved in modulating the permeability of the blood vessels during the body’s immune response.

“The mechanism discovered will yield a completely new approach for the development of drugs to combat metastasis in breast, prostate, and bowel cancer,” Dr. Borsig is convinced. Suppressing the tumor’s chemokine expression or blocking the doorman specifically for the tumor chemokine to inhibit cancer cells from entering healthy tissue from the bloodstream is conceivable. “If we can succeed in preventing the cancer cells from leaving the bloodstream, the metastasis can be fought directly at the source,” concludes Dr. Borsig.

Related Links:

University of Zurich






Print article

Channels

Genomics/Proteomics

view channel
Image: The first 3D map of the cancer-associated protein DCLK1 (doublecortin-like kinase 1), revealed how it functions (Photo courtesy of Walter and Eliza Hall Institute).

Kinase Domain Mutation Causes Protein Malfunction and Tumor Development

A team of chemical biologists has generated the first molecular map of the protein doublecortin kinase like domain 1 (DCLK1), a factor linked to more than 10% of gastric cancers that has also been found... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.